Brad H Rovin Samir V Parikh
10.1053/j.ajkd.2013.11.023
Am J Kidney Dis
2014 Apr;63(4):677-90.
lupus nephritis biologics novel therapies small molecules systemic lupus erythematosus (sle)
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/24411715/
Immunosuppressive Agents / therapeutic use Lupus Nephritis / drug therapy
Immunosuppressive Agents / therapeutic use Lupus Nephritis / drug therapy Case Reports Research Support, N.I.H., Extramural Review Abatacept Acute Kidney Injury / etiology Acute Kidney Injury / immunology Adolescent Algorithms Antibodies, Monoclonal, Humanized / therapeutic use Antibodies, Monoclonal, Murine-Derived / administration & dosage Apoptosis / immunology Autoantibodies / metabolism B-Lymphocytes / drug effects B-Lymphocytes / immunology Cytokine TWEAK Drug Therapy, Combination Female Genetic Predisposition to Disease Humans Immunoconjugates / pharmacology Immunoconjugates / therapeutic use Immunosuppressive Agents / administration & dosage Immunosuppressive Agents / pharmacology Interleukin-6 / antagonists & inhibitors Lupus Erythematosus, Systemic / genetics Lupus Nephritis / complications Lupus Nephritis / immunology Lupus Nephritis / pathology Quinolones / therapeutic use Remission Induction Rituximab Tumor Necrosis Factor Inhibitors Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived Autoantibodies Cytokine TWEAK Immunoconjugates Immunosuppressive Agents Interleukin-6 Quinolones TNFSF12 protein, human Tumor Necrosis Factor Inhibitors Rituximab Abatacept laquinimod eculizumab
PMC4159074
24411715
Lupus nephritis: the evolving role of novel therapeutics
2014